Hero image

Research & products

We run to, not from, the world’s biggest health challenges.

The journey to invention and discovery is guided by science – and inspired by patients

Our purpose is to save and improve lives for generations. Our strategy is simple: We follow the science. The path to discovery is often unclear, but we are tireless in seeking solutions for some of the world’s most difficult health challenges.

Our work in numbers

15.6K

people employed in research and development

357M

people reached through our major programs and partnerships

$9.9B

invested in R&D in 2019

We address the world’s most difficult health challenges, following world-class science

Hero_RGB_Discovery-Blue
Discovery & development

Step inside Merck Research Laboratories (MRL) where our quest to save and improve lives through research and development begins

B5 - Our pipeline__
Pipeline

We’re focused on inventing new medicines and vaccines to help more people

B5 we work to deliver
Products

Our focus on breakthrough science is working

Clinical trials

Our progress is due in large part to the important and tough scientific questions we set out to answer with our trials and collaborations. We are grateful to the thousands of volunteers who participate in our clinical trials – making this all possible.

Father playing with young son at breakfast table

Our commitment to patients is unwavering

As long as there are still patients in hospitals, doctors and nurses desperate to add years to the lives of their patients, and a world where treatments aren’t accessible to all, we will be here, fighting with all we have to deliver more, sooner.

Invention begins here

Our scientists are applying the latest groundbreaking research technologies and revolutionizing how we discover and develop medicines and vaccines

View our stories

Confronting a new era in immunization

By John Markels, Ph.D., president, Merck Vaccines

Read more

Next: Confronting a new era in immunization

Merck’s response to Ebola outbreaks

Along with international agencies and governments, Merck has played — and continues to play — a leadership role in responding to Ebola.

Read more

Next: Merck’s response to Ebola outbreaks

Merck scientists probe how our bodies’ bugs impact immunity and disease

Our researchers are pioneering new ways to research and understand the biology of new diseases by looking inside the human gut

Discover how

Next: Merck scientists probe how our bodies’ bugs impact immunity and disease

Experts meet to discuss health care innovations during COVID

Merck’s chief patient officer, Julie Gerberding, joins the Fortune Global Forum to discuss breakthrough innovations in health care

More from Julie

Next: Experts meet to discuss health care innovations during COVID

Our third-quarter 2020 financial results

Merck announced third-quarter worldwide sales of $12.6 billion – an increase of 1% compared with the third quarter of 2019. Excluding the impact from foreign exchange, sales grew 2%. The company anticipates full-year 2020 revenue range to be between $47.6 billion and $48.6 billion, including a negative impact from foreign exchange of approximately 1.5%. Take […]

Read more

Next: Our third-quarter 2020 financial results

Previous
Next